Subscribe to Search results

Regional transfusion centres highlighted that blood screening did not occur across the board in respect of whole blood until 1972.

Published on:

Dr John Craske and Dr Peter Kirk published a report stating that further research was required to assess the incidence of chronic liver disease after non-B Hepatitis.

Published on:

Dr Vivian Mitchell noted that for at least some haemophilia patients treated with factor concentrates chronic liver disease could be progressive.

Published on:

Dr David Dane relayed to Dr Sheila Waiter that viruses might also be found among other transfused individuals because the non-A non-B Hepatitis viruses may be responsible for abnormal livers which were evidently common among people with haemophilia.

Published on:

Mr Justice Burton held that there was a significant degree of seriousness with which non-A non-B Hepatitis was regarded according to the letter in which chief scientists told the Medical Research Council that the DHSS had given hepatitis high priority.

Published on:

Dr John Craske noted studies in people with haemophilia showed that non-A non-B Hepatitis might severely damage the liver and up to 40% of non-A non-B Hepatitis infections progressed to chronic liver disease.

Published on:

Feinstone et al published an article in The New England Journal of Medicine in 1975, noting that transfusion-associated hepatitis was not due to viral hepatitis type A or B.

Published on:

Dienstag et al published an article in The Lancet in 1977 titled "Non-A, Non-B Post-Transfusion Hepatitis".

Published on:

Koretz et al published an article in 1976 regarding post-transfusion chronic liver disease.

Published on:

Alter et al published an article in The Lancet in 1978 regarding a transmissible agent in non-A non-B Hepatitis.

Published on:

The NETR Association of Haematologists Haemophilia Working Party published guidelines on the screening and investigation of hepatic disease in patients with congenital coagulation disorders.

Published on:

Professor John Dillon gave evidence to the Inquiry about the distinction between acute non-A non-B Hepatitis and chronic non-A non-B Hepatitis.

Published on:

Liver biopsies undertaken at Sheffield Children's Hospital showed that five boys with haemophilia whose liver function was persistently abnormal had "confirmed underlying chronic liver damage, ranging from chronic persistent hepatitis to chronic aggressive hepatitis with early cirrhosis." Only one had serological evidence of previous Hepatitis B infection.

Published on:

Professor Howard Thomas gave evidence to the Inquiry that previous studies and evidence regarding concerns about non-A non-B Hepatitis in the late 1970s and early 1980s were 'all in accord'.

Published on:

In a haemophilia centre director's meeting, Dr Craske stated that "Large pool concentrates appeared to give a higher risk of hepatitis than small pooled concentrates and Dr Craske felt that increased usage of small pooled concentrates would help to reduce the incidence of hepatitis in the haemophilic population".

Published on:

Dr Aronstam published a paper identifying that hepatitis transmitted as a result of a receiving blood/a blood product carried a risk of serious long-term consequences.

Published on:

Dame Sheila published a textbook titled "Disease of the Liver and Biliary Systems", which canvassed the known effects of non-A non-B Hepatitis on the liver and biliary systems.

Published on:

Professor Ian Franklin gave evidence to the Inquiry that Dame Sheila "didn't really know what was going to be happening" when reflecting on the findings in her textbook 'Disease of the Liver and Biliary Systems'.

Published on:

Norkrans et al published a study which concluded that: "It is evident that the risk of transmitting hepatitis non-A, non-B is high with factor VIII preparations obtained from large plasma pools".

Published on:

Holland and Alter published "Non-A, Non-B Viral Hepatitis Human Pathology", which said that "whenever possible, autologous blood and blood products with the lowest risks of hepatitis transmission should be utilized, e.g., the use of single donor plasma or small pools of cryoprecipitated antihemophilic factor in preference to concentrates of clotting factors made from large pools of donors, some of whom are almost certain to be carriers of non-A, non-B hepatitis virus."

Published on: